Clinical Trials
17
Active:1
Completed:8
Trial Phases
3 Phases
Phase 1:9
Phase 2:3
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (52.9%)Phase 3
5 (29.4%)Phase 2
3 (17.6%)Safety and Immunogenicity Study of SCB-1019T in Children
Phase 1
Withdrawn
- Conditions
- RSV Infection
- Interventions
- Biological: low dose SCB-1019TBiological: adjuvanted low dose SCB-1019TOther: PlaceboBiological: high dose SCB-1019TBiological: adjuvanted high dose SCB-1019T
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT06666179
- Locations
- 🇦🇺
The Kids Research Institute, Perth, Western Australia, Australia
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
Phase 3
Withdrawn
- Conditions
- COVID-19
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT06567457
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Vaccination
- Interventions
- Biological: Candidate vaccine, SCB-1019Biological: placeboBiological: candidate vaccine, SCB-1019T
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty
- Target Recruit Count
- 160
- Registration Number
- NCT06194318
- Locations
- 🇦🇺
Fusion Clinical Research, Adelaide, Southern Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
Phase 3
Withdrawn
- Conditions
- COVID-19
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT05926440
- Locations
- 🇵🇭
Health Index Multispecialty Clinic, Manila, Philippines
🇵🇭Manila Doctors Hospital, Manila, Philippines
🇵🇭Tropical Disease Foundation, Putatan, Philippines
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Target Recruit Count
- 153
- Registration Number
- NCT05228314
- Locations
- 🇿🇦
Josha Research, Bloemfontein, South Africa
🇿🇦Global Clinical Trials (Pty) Ltd, Pretoria, South Africa
🇿🇦Wits Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, Soweto, South Africa
- Prev
- 1
- 2
- 3
- Next
News
No news found